| __timestamp | Amicus Therapeutics, Inc. | Lantheus Holdings, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 20717000 | 72429000 |
| Thursday, January 1, 2015 | 47269000 | 78634000 |
| Friday, January 1, 2016 | 71151000 | 75374000 |
| Sunday, January 1, 2017 | 88671000 | 92157000 |
| Monday, January 1, 2018 | 127200000 | 93326000 |
| Tuesday, January 1, 2019 | 169861000 | 103132000 |
| Wednesday, January 1, 2020 | 156407000 | 110171000 |
| Friday, January 1, 2021 | 192710000 | 218817000 |
| Saturday, January 1, 2022 | 213041000 | 233827000 |
| Sunday, January 1, 2023 | 275270000 | 267194000 |
In pursuit of knowledge
In the competitive landscape of the pharmaceutical and biotechnology sectors, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Lantheus Holdings, Inc. and Amicus Therapeutics, Inc. have demonstrated distinct strategies in optimizing these costs.
From 2014 to 2023, Amicus Therapeutics saw a staggering 1,230% increase in SG&A expenses, reflecting its aggressive expansion and investment in growth. In contrast, Lantheus Holdings experienced a more moderate 269% rise, indicating a more controlled approach to cost management.
By 2023, both companies reported SG&A expenses nearing $270 million, showcasing their commitment to scaling operations. However, the differing growth rates highlight their unique strategic priorities. As investors and industry analysts evaluate these trends, understanding the balance between cost management and growth potential becomes essential for predicting future performance.
Eli Lilly and Company vs Amicus Therapeutics, Inc.: SG&A Expense Trends
Novo Nordisk A/S or Lantheus Holdings, Inc.: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Amicus Therapeutics, Inc. Trends and Insights
Alnylam Pharmaceuticals, Inc. and Amicus Therapeutics, Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and Lantheus Holdings, Inc.
Genmab A/S and Lantheus Holdings, Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Lantheus Holdings, Inc. and Corcept Therapeutics Incorporated
Comparing SG&A Expenses: Lantheus Holdings, Inc. vs Soleno Therapeutics, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Lantheus Holdings, Inc. and Perrigo Company plc
Operational Costs Compared: SG&A Analysis of Lantheus Holdings, Inc. and HUTCHMED (China) Limited
Who Optimizes SG&A Costs Better? Lantheus Holdings, Inc. or Taro Pharmaceutical Industries Ltd.
Selling, General, and Administrative Costs: Amicus Therapeutics, Inc. vs Arrowhead Pharmaceuticals, Inc.